Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. Methods In a multicenter, noninferiority trial, we randomly assigned hospitalized patients (including patients in the intensive care unit [ICU]) who had bloodstream infection to receive antibiotic treatment for 7 days or 14 days. Antibiotic selection, dosing, and route were at the discretion of the treating team. We excluded patients with severe immunosuppression, foci requiring prolonged treatment, single cultures with possible contaminants, or cultures yielding Staphylococcus aureus . The primary outcome was death from any cause by 90 days after diagnosis of the bloodstream infection, with a noninferiority margin of 4 percentage points. Research Summary Antibiotic Treatment for 7 or 14 Days for Bloodstream Infection Results Across 74 hospitals in seven countries, 3608 patients underwent randomization and were included in the intention-to-treat analysis; 1814 patients were assigned to 7 days of antibiotic treatment, and 1794 to 14 days. At enrollment, 55.0% of patients were in the ICU and 45.0% were on hospital wards. Infections were acquired in the community (75.4%), hospital wards (13.4%) and ICUs (11.2%). Bacteremia most commonly originated from the urinary tract (42.2%), abdomen (18.8%), lung (13.0%), vascular catheters (6.3%), and skin or soft tissue (5.2%). By 90 days, 261 patients (14.5%) receiving antibiotics for 7 days had died and 286 patients (16.1%) receiving antibiotics for 14 days had died (difference, −1.6 percentage points [95.7% confidence interval {CI}, −4.0 to 0.8]), which showed the noninferiority of the shorter treatment duration. Patients were treated for longer than the assigned duration in 23.1% of the patients in the 7-day group and in 10.7% of the patients in the 14-day group. A per-protocol analysis also showed noninferiority (difference, −2.0 percentage points [95% CI, −4.5 to 0.6]). These findings were generally consistent across secondary clinical outcomes and across prespecified subgroups defined according to patient, pathogen, and syndrome characteristics. Conclusions Among hospitalized patients with bloodstream infection, antibiotic treatment for 7 days was noninferior to treatment for 14 days. (Funded by the Canadian Institutes of Health Research and others; BALANCE ClinicalTrials.gov number, NCT03005145 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biomarker-guided strategies, randomized trials of bloodstream infection duration, and recent meta-analyses have shown that less antibiotic exposure can be appropriate in selected patients when clinical stability and source control are present (24–29).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [26]
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Ikuta, K. S., Swetschinski, L. R., Robles Aguilar, G., Sharara, F., Mestrovic, T., Gray, A. P., Davis Weaver, N., Wool, E. E., Han, C., Gershberg Hayoon, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02185-7 · Cited by 2,235
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Chastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., et al. (2003) · JAMA · doi:10.1001/jama.290.19.2588 · Cited by 1,376
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
Iversen, K., Ihlemann, N., Gill, S. U., Madsen, T., Elming, H., Jensen, K. T., Bruun, N. E., Høfsten, D. E., Fursted, K., Christensen, J. J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808312 · Cited by 824
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
Goto, M., & Al-Hasan, M. N. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12195 · Cited by 752
Trial of short-course antimicrobial therapy for intraabdominal infection.
Sawyer, R. G., Claridge, J. A., Nathens, A. B., Rotstein, O. D., Duane, T. M., Evans, H. L., Cook, C. H., O’Neill, P. J., Mazuski, J. E., Askari, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411162 · Cited by 747
Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., & Leibovici, L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00627-10 · Cited by 724
Cited by
Singer, M., Angus, D., Annane, D., Bauer, M. W., Kalil, A. C., Klompas, M., Machado, F. R., Martin, G. S., Randolph, A. G., Shankar‐Hari, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02422-5 · Cited by 83
Lee, T. C., Prosty, C. J., Fralick, M., Huttner, A., McDonald, E. G., Molina, J., Paul, M., Pinto, R., Rishu, A., von Dach, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.1421 · Cited by 30
Antibiotic therapy for severe bacterial infections
Timsit, J., Ling, L., de Montmollin, É., Bracht, H., Morris, A. C., Bus, L. D., Falcone, M., Harris, P. N. A., Machado, F. R., Paiva, J.-A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08063-0 · Cited by 47
Marıno, A., Augello, E., Bellanca, C. M., Cosentino, F., Stracquadanio, S., Via, L. L., Maniaci, A., Spampinato, S., Fadda, P., Cantarella, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146905 · Cited by 33
Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection
Gilboa, M., Regev‐Yochay, G., Meltzer, E., Cohen, I., Peretz, Y., Zilberman‐Daniels, T., Segev, A., Amit, S., Yahav, D., & Barda, N. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.25252 · Cited by 27
Trautner, B. W., Cortes-Penfield, N. W., Gupta, K., Hirsch, E. B., Horstman, M. J., Moran, G. J., Colgan, R., O’Horo, J. C., Ashraf, M. S., Connolly, S. J., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf462 · Cited by 49
Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship
Acierno, C., Nevola, R., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Caturano, A. (2025) · Biomedicines · doi:10.3390/biomedicines13061343 · Cited by 23
Prosty, C. J., Noutsios, C. D., Dubé, L.-R., Baden, R. P., Davar, K., Freling, S., Bhuket, T. P., Yee, H. F., Spellberg, B. J., McDonald, E. G., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.3832 · Cited by 24
Current standard of care for septic shock
Delaney, A. P., Borges-Sa, M., Chew, M. S., Waele, J. J. D., Dye, J., Khanna, A. K., Hamzaoui, O., Hammond, N. E., Glenn Hernández, P., Herridge, M. S., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08211-6 · Cited by 24
Ong, S. W. X., Mahar, R. K., Selman, C. J., Pinto, R. L., Davis, J. S., Fowler, R., Tong, S. Y. C., & Daneman, N. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf314 · Cited by 22
Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience
Bayless, D. R., Dumais, M. G., McHugh, J., Ranganath, N., Fida, M., Chesdachai, S., & Saleh, O. A. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00724-25 · Cited by 24
Maraolo, A. E., Gatti, M., Principe, L., Marıno, A., Pipitone, G., PASCALE, G. D., & Ceccarelli, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2487163 · Cited by 19
Antibiotic De-Escalation in the Intensive Care Unit: Rationale and Potential Strategies
Singer, S., Kolodziej, L. E., Micek, S. T., & Kollef, M. H. (2025) · Antibiotics · doi:10.3390/antibiotics14050467 · Cited by 21
“Most recently, the multicenter, randomized BALANCE trial showed that 7 days of antibiotics was non-inferior to 14 days for hospitalized patients with bloodstream infections for the outcome of 90-day mortality (14.5% vs. 16.1%, 95% CI [ − 4.0 to 0.8]) [72].”
InfluentialZahavi, I., Kunwar, D., Olchowski, J., Dallasheh, H., & Paul, M. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.04.008 · Cited by 16
Optimal antibiotic use in the intensive care unit
Micek, S. T., Vazquez Guillamet, M. C., Reynolds, D., Matuszak, S., Kolodziej, L., & Kollef, M. H. (2025) · Critical Care · doi:10.1186/s13054-025-05653-8 · Cited by 11
Ong, S. W. X., Pinto, R. L., Rishu, A. H., Tong, S. Y. C., Commons, R. J., Conly, J. M., Evans, G. A., Fralick, M., Kandel, C. E., Lagacé-Wiens, P. R. S., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103195 · Cited by 11
Paniagua‐García, M., Guisado-Gil, A. B., Molina, J., Peñalva, G., Álvarez‐Marín, R., Pachón-Ibáñez, M. E., & Cisneros, J. M. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103310 · Cited by 8
Tabah, A., Waele, J. J. D., Kai, N. S. Y., Aslan, A. T., Buetti, N., Timsit, J., Ballard, E. L., Eriksson, L., Laupland, K. B., & Lipman, J. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08026-5 · Cited by 11
Gupta, S., Klompas, M., & Rhee, C. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf336 · Cited by 17
Liu, M., Gao, Y., Li, Z., Li, Z., Yao, L., Xu, J., Zheng, Q., Zeng, P., & Tian, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103397 · Cited by 7
“16 However, the optimal duration of antibiotic treatment for bacterial bloodstream infections remains a subject of intense debate.”
Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections
Geng, S., Tang, Q., & Shi, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1653424 · Cited by 16
“%) compared to a 14-day regimen (16.1%), with signi fi cantly reduced antibiotic exposure (median 8 vs. 14 days) and no increased risk of relapse or secondary resistant infections, supporting the feasibility of short-course therapy in critically ill patients (Daneman et al., 2025).”
InfluentialLin, T.-H., Chung, H., Jian, M., Chang, C.-K., Perng, C., Chang, F., Chen, Y.-H., & Shang, H. (2025) · Implementation Science · doi:10.1186/s13012-025-01453-4 · Cited by 10
Dutta, S., Kabra, N. S., Saini, S. S., Anne, R. P., Kadam, S. S., Rameshbabu, M., Khurana, S., & Kiran, S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103543 · Cited by 9
“59,60 Evidence suggests that unnecessarily prolonged antibiotic courses are linked to increased adverse events (AEs) and the development of antimicrobial resistance (AMR).”
Majeed, A., & Rust, T. C. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00124 · Cited by 7
Berre, C. L., Degrendel, M., Houard, M., Benetazzo, L., Vachée, A., Georges, H., Wallet, F., Patoz, P., Bortolotti, P., Nseir, S., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14040358 · Cited by 6
“Finally, the recently published BALANCE trial showed that a 7-day antibiotic treatment was non-inferior to a 14-day antibiotic treatment in hospitalized patients with BSI including ICU patients [26].”
Update on sepsis and septic shock: from bundles to precision medicine
Plata-Menchaca, E. P., Iba, T., & Ferrer, R. (2026) · Intensive Care Medicine · doi:10.1007/s00134-025-08291-4 · Cited by 8
Infection after cesarean delivery: diagnosis, pathophysiology, management, and prevention
Duff, P. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.08.007 · Cited by 9
Oral switch antibiotic therapy in uncomplicated Enterococcus faecalis bloodstream infection
Mansi, S. A., Pokalsky, M., Turnley, K., Freeman, A., Bookstaver, P. B., Kohn, J. E., Winders, H. R., Withers, S. T., & Al‐Hasan, M. N. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf004 · Cited by 5
Armstrong, E., Kulikova, M., Yee, N., Rishu, A. H., Muscedere, J., Sibley, S. R., Maslove, D. M., Boyd, J. G., Evans, G. A., Detsky, M. E., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf137 · Cited by 5
“Complete trial details can be found in the BALANCE trial and protocol publications [12, 13].”
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
Daneman, N., & Fowler, R. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2506050 · Cited by 5
Kumar, A., Kumar, A., Tyagi, A., Singh, R., & Charaya, M. U. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05577-3 · Cited by 7
Doernberg, S. B., Heil, E. L., Fiawoo, S., Lee, J. H., Cosgrove, S. E., Dobrzynski, D., Li, Y., Shields, R. K., Spivak, E. S., Stohs, E. J., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70160 · Cited by 5
Prager, M., Bergmann, F., Pracher, L., Copic, D., Zessner‐Spitzenberg, J., Gelbenegger, G., Lagler, H., Harrison, N. M., Burgmann, H., Zeitlinger, M. A., et al. (2025) · Infection · doi:10.1007/s15010-025-02562-4 · Cited by 5
“Despite increasing evidence supporting the non-infe - riority of shorter courses of antibiotic therapy [ 4, 6, 7, 8, 10–15], prolonged treatment durations of up to 14 days are still commonly used [ 16, 17] and recommended by current guidelines [ 18, 19].”
InfluentialClinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
Ong, S. W. X., Pinto, R. L., Rishu, A. H., Tong, S. Y. C., Fowler, R., & Daneman, N. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf294 · Cited by 4
Seo, J.-W., Kim, D. Y., Yoon, Y., Lyu, Y. S., Na, Y. S., Moon, D. S., Yun, N. R., Kim, M. S., Kim, J., Bae, S. W., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag345 · Cited by 4
Sutton, J. D., Lee, J. H., Howard, K., Quartuccio, K. S., McCoy, C. P., Gupta, A. K., Slish, J. C., Engers, D. W., Malani, A. N., Karaba, S. M., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf298 · Cited by 3
Serapide, F., Rotundo, S., Gallelli, L., Palleria, C., Colosimo, M., Gullì, S. P., Marcianò, G., & Russo, A. (2025) · Antibiotics · doi:10.3390/antibiotics14070727 · Cited by 4
Hsu, J.-T., Lin, C., Hung, S., Chung, S., & Cheng, P. (2025) · BMC Urology · doi:10.1186/s12894-025-01868-7 · Cited by 3
“Antibiotic treatment for sepsis is suggested from days 7–14 [14].”
Mateu, A., Martínez-Urrea, A., Gallego, C., Gisbert, L. M., Dietl, B., Xercavins, M., López-Sánchez, M., Álvarez, S., Rodríguez, S., Roselló, T., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14080751 · Cited by 3
“Previous RCTs [3–5] have investigated transitioning to oral antibiotics for E-BSI but involved selective patient groups or delayed the oral switch beyond current recommendations, which suggest a 7-day course for uncomplicated E-BSIs [13–15].”
Daneman, N., Johnstone, J., Lee, T. C., MacFadden, D. R., McDonald, E. G., Morpeth, S. C., Ong, S. W. X., Paterson, D. L., Pinto, R. L., Rishu, A. H., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101588 · Cited by 3
“Each domain had additional selection criteria, such that only a subset of BALANCE+ platform patients were eligible for each domain (table 1).”
Alotaibi, M. A. M., Almohaya, A. M., Bitterman, R., Molina, J., Orchanian‐Cheff, A., & Husain, S. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70209 · Cited by 3
“Over the recent years, at least four randomized controlled trials (RCTs) investigated the efficacy and safety of shorter versus longer antibiotic courses in variable patient populations with uncomplicated GN-BSIs [ 6–9 ].”
Tebano, G., Convertino, C., Raumer, L., Sgarzani, R., Melandri, D., & Cristini, F. (2026) · European Burn Journal · doi:10.3390/ebj7020035 · Cited by 2
“Antibiotic treatment of 7 days for bacteremia and 7 days or less for pneumonia is strongly supported by evidence in the general population [146–149].”
Dezza, F. C., Pulido, L. B., Borreguero, I., Pérez, F. M. D., Jiménez, V. P., Riestra, S. D. L. R., Bravo-Ferrer, J. M., Palacios-Baena, Z. R., Zuñiga, M. Á. L., Cobo, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00760-9 · Cited by 4
Infectious Diseases: What You May Have Missed in 2024
Hamed, H. K. A., Nachman, A., Riopel, N., & Schuster, M. G. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00925 · Cited by 3
Wu, C.-W., Lai, C., Wu, J., & Lee, M.-C. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102852 · Cited by 3
Editorial: Progressing the understanding and management of bloodstream infections
Wang, L., Lin, B., Gong, X., & Yu, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1562934 · Cited by 3
Zhao, C., Chen, C., Lu, D., Cai, K., Hu, W., & Mao, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1617328 · Cited by 2
Bassetti, M., Vena, A., & Giacobbe, D. R. (2025) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001150 · Cited by 3
Luna, G., Rodríguez, A., Igbonagwam, C., Barakat, Z., Somoza, D. C., Khan, Z., Snyder, G., Soliman, M. K., Dibo, I., & Sabina, M. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01258-4 · Cited by 3
Yahav, D., Pinto, R. L., Cook, D. J., Davis, J. S., Duan, E. H., Hoffman, T., Lee, T. C., McDonald, E. G., Morpeth, S. C., Muscedere, J., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag144 · Cited by 4
Hamani, M., Pinto, R. L., Lee, T. C., MacFadden, D. R., McDonald, E. G., Sligl, W., Fowler, R., Daneman, N., Daneman, N., Rishu, A., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.06.003 · Cited by 2
Management of Infected Wounds: A Wound Healing Foundation Consensus Statement
Cortes-Penfield, N. W., Lipsky, B. A., Eriksson, E. K., Brennan, M. B., Clauss, M., Dunyach‐Remy, C., Gardner, S. E., Hayda, R. A., Kalan, L., Kim, P. J., et al. (2026) · Advances in Wound Care · doi:10.1177/21621918261459794 · Cited by 3
Mudrik‐Zohar, H., Ong, S. W. X., Tong, S. Y. C., Hornik‐Lurie, T., Sabbah, A., Weinstein, O., & Chowers, M. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag387 · Cited by 2
“The BALANCE clinical trial showed that 7-day treatment duration is noninferior to 14 days for patients with uncomplicated BSI [24], however this was nonpathogen-specific, and clinical trials focused specifically on optimal duration for enterococcal BSI are still lacking.”
InfluentialMajor publications in the critical care pharmacotherapy literature: 2024
Esteves, A. M., Bernardoni, B., Brown, S., Farrar, J. E., Filiberto, D. M., Kopp, B. J., Li, J., Madorsky, M., Moore, M. J., Perrodin, J., et al. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155177 · Cited by 2
Bonazzetti, C., Grechi, A., Gibertoni, D., Mangione, L., Todisco, F., Tonnini, M., Piscaglia, F., Caraceni, P., Calogero, P., Borghi, C., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf680 · Cited by 1
Sepsis management in the antimicrobial resistance era
Esposito, S., Salzano, F., Ascione, T., D’Amore, C., Spera, A. M., Conti, V., Franci, G., & Pagliano, P. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2595466 · Cited by 2
Chen, B., Shu, W., Le, J., & Jin, D. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12111-x · Cited by 1
Significant Publications on Infectious Diseases Pharmacotherapy in 2024
Lee, L., Huang, Y.-H., Shaikhli, H. A., Billah, P., Nguyen, N., Thomas, J. L., Zaki, A. M., & Lin, K. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251408307 · Cited by 1
Dauer der Antibiotikatherapie – wie kurz ist kurz genug?
Hitzenbichler, F. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-02030-z · Cited by 1
“In den oben erwähnten Bakteriämiestu-dien sind einzelne Erreger immer ausge-nommen: Candida sp. und S. aureus .”
Short-Course Therapy for Uncomplicated VRE Bacteremia: This is Us Trying (to Shorten Therapy)
Torres, E., Hlavacek, N. L., & Cabanilla, M. G. (2025) · Journal of Pharmacy Technology · doi:10.1177/87551225251396748 · Cited by 1
What's Hot This Year in ID Clinical Science 2025
Freiberg, J. A., & Wright, P. F. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf740 · Cited by 1
“With over 3600 patients across 7 countries, the BALANCE RCT was the largest and most inclusive known study of antibiotic durations in bacteremia [11].”
Antimicrobial Stewardship for the Infection Control Professional
Hawkins, M. R., Pogue, J. M., & Zhou, S. (2026) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.12.009 · Cited by 1
Gut check: antimicrobial stewardship opportunities in intra-abdominal infections
Prasad, R., Arya, R., Medvedeva, N., Ha, D. R., & Holubar, M. K. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2025.10169 · Cited by 2
“30 Observational studies signaled an increased risk of recurrence with stepdown to oral beta-lactam agents compared with fluoroquinolones or trimethoprim/ sulfamethoxazole.”
MacPhail, A., Loke, J. C. T., Houston, B. L., Dendle, C., Henden, A. S., Weinkove, R., Morrissey, O., Neofytos, D., Buetti, N., Parker, C., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70358 · Cited by 1
Overdevest, A. G., Sieswerda, E., Haal, S., Bogaards, J. A., Baven‐Pronk, M. A. M. C., Bogte, A., Boparai, K. S., ter Borg, F., Brink, M. A., van Delft, F., et al. (2026) · Trials · doi:10.1186/s13063-026-09524-7 · Cited by 2
“Evidence has been accumulating that many other bacterial infections, including abdominal and bloodstream infections, can be treated with shorter antibiotic therapy than previously assumed [14–18].”
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Mackow, N., Shao, W., Ge, L., Komarow, L., Jiang, J., Boutzoukas, A. E., Chen, L., Garcia‐Diaz, J., Herc, E. S., Doi, Y., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag160 · Cited by 1
Wang, L., Yang, F., Zhou, C., Yang, X., Rong, J., Chi, X., Guo, R., Li, N., Sheng, L., Jiang, L., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1699905 · Cited by 3
“This optimization reduced diagnostic delays, facilitated earlier de-escalation of broad-spectrum empirical therapy and mitigated unnecessary antimicrobial use – crucial advantages in combating antimicrobial resistance (Weinbren et al., 2018; Adamik et al., 2020; Daneman et al., 2025).”
Luo, R., Wade, E., Bertsch, R. A., Clutter, D. S., & Skarbinski, J. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag200 · Cited by 1
Antibiotic use in serious infections
Kolodziej, L. E., Matuszak, S., & Micek, S. T. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001389 · Cited by 1
Abi Manesh, S., & Paterson, D. L. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag347 · Cited by 1
Ramendra, R., Wright, J. K., Kain, K. C., Kim, B., Mishra, H. K., Zhong, K., Aslanian, P., Carignan, A., Conly, J. M., Detsky, M. E., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20973 · Cited by 2
Understanding the Clone–Censor–Weight Method in Observational Studies of Antibiotic Duration
Parienti, J. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag388 · Cited by 1
Armstrong, E., Pinto, R. L., Kulikova, M., Yee, N., Rishu, A., Muscedere, J., Sibley, S. R., Maslove, D. M., Boyd, J. G., Evans, G. A., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag460 · Cited by 3
What place for pragmatic RCTs in intensive care?
Singer, M., & Vincent, J. (2026) · Critical Care · doi:10.1186/s13054-026-06242-z · Cited by 1
“The BALANCE trial is an excellent recent example [28].”
Investigator-initiated randomized clinical trials in infectious diseases: the BALANCE experience
Daneman, N., Rishu, A. H., Pinto, R. L., Arabi, Y. M., Cook, D. J., Hall, R., Muscedere, J., Parke, R. L., Reynolds, S., Rogers, B. A., et al. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.02.033 · Cited by 1
Patamatamkul, S. (2025) · IJID Regions · doi:10.1016/j.ijregi.2025.100639 · Cited by 1
“Conversely, the PP analysis, despite reduced power and loss of randomization, demonstrated no increased mortality in the 7-day group, further supporting the trial’s findings [ 10 ].”
InfluentialPruc, M., Masłyk, M., Krupa, A., & Szarpak, Ł. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07919-9 · Cited by 1
Shorter antibiotic courses for bloodstream infections can reduce healthcare spending
Biebelberg, B. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07952-8 · Cited by 1
Ventilator-associated pneumonia
Jayasimhan, D., & Young, P. J. (2025) · BJA Education · doi:10.1016/j.bjae.2025.07.002 · Cited by 2
Schmidt, J. B., Nielsen, K. L., Strunin, D., Kirkby, N., Thomassen, J., Rasmussen, S. C., Frikke-Schmidt, R., Hertz, F., & Engsig-Karup, A. (2025) · medRxiv · doi:10.1101/2025.01.21.25320878 · Cited by 1
Eight Days a Week — BALANCING Duration and Efficacy
Fowler, V. G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2414037 · Cited by 1
Zhang, Y., Liao, G., Song, J., Liao, Y., & Zhang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1924203
Lanthier, L., Carignan, A., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.01.007
Liu, M., Gao, Y., Li, Z., Li, Z., Yao, L., Xu, J., Zheng, Q., Zeng, P., & Tian, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5200014
Are Procalcitonin Measures a Reliable Predictor of Stopping Antibiotics Among Patients With Sepsis?
Hsu, C., & Lai, C.-C. (2025) · JAMA · doi:10.1001/jama.2025.0782
Gajdos, L., Buetti, N., Tabah, A., & Timsit, J. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07927-9
Research Progress in the Treatment of Pediatric Staphylococcus aureus Bloodstream Infection
张, 卓. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551423
Evidenz für kurzes Antibiotika-Regime bei Sepsis gestärkt
Klein, F. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2509-9976
Sepsis Today: Diagnostic Misconceptions and Failure of Uniform Treatment Principles
Klepikov, I. (2025) · Archives of Pulmonology and Respiratory Care · doi:10.17352/aprc.000092
Editorial: Current evidence on epidemiology and management of infections in critically ill patients
Dardón-Fierro, F. E., Ferrer, R., & Plata-Menchaca, E. P. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1584879 · Cited by 2
Ventilator-associated pneumonia: how long is long enough?
Koulenti, D., Almyroudi, M. P., & Katsounas, A. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001298 · Cited by 1
Cisneros, J. M., Peñalva, G., Cantón, R., Rodríguez, M. D. L. M. B., González‐López, J. J., Rodríguez‐Baño, J., & Paño‐Pardo, J. R. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101393
Miwa, T., Okamoto, K., Fukasawa, K., Yamaguchi, R., Yamamoto, T., & Tsutsumi, T. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf130
Gram-negative bloodstream infections: where can we do better? A retrospective cohort study
Guit, M., Tanida, K., Degel-Brossmann, N., Christner, M., Aepfelbacher, M., Rohde, H., & Olearo, F. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05231-4
Seven versus fourteen days of antibiotic therapy in bloodstream infections: the BALANCE trial
Sciarrone, P., Sciacca, B., Manicardi, F., Buduo, E. D., Tarasconi, E., & Scuola di metodologia della ricerca, S. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04086-z
Evidenz für kurzes Antibiotika-Regime bei Sepsis gestärkt
Klein, F. (2025) · Infektiologie up2date · doi:10.1055/a-2645-2759
Evidenz für kurzes Antibiotika-Regime bei Sepsis gestärkt
(2025) · Journal Club AINS · doi:10.1055/a-2570-6847
Mori, G., Zandonà, E., Campomori, A., Scarparo, C., Urru, S. A. M., Stevanin, G., Lorenzin, G., Ripa, M., Castelli, A., Prezzavento, A., et al. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf160
Evidenz für kurzes Antibiotika-Regime bei Sepsis gestärkt
Klein, F. (2025) · Intensivmedizin up2date · doi:10.1055/a-2662-2033
Ting, R. S., Sher, D., Jang, B., Agarwal, S., Farrelly, R., Rosenthal, R., Miyakis, S., & Trantalis, J. N. (2025) · Shoulder & Elbow · doi:10.1177/17585732251388929
Metadata
- Authors
- The BALANCE Investigators
- Corresponding author
- The BALANCE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-13
- Volume
- 392
- Issue
- 11
- Pages
- 1065-1078
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404539334
- Cited by
- 158
- References
- 33
- Citations by year
- 2026: 80 · 2025: 76
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- New Zealand Health Research Council
- Canadian Institutes of Health Research
- Physicians Services Incorporated Ontario
- Australian National Health Medical Research Council
- Physicians Services, by the Ontario Ministry of Health Alternate Funding Plan Innovation Fund
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- bloodstream infection, bacteremia, antibiotic duration, non-inferiority, mortality, intensive care unit patients, community-acquired infections, urinary tract infection
- MeSH terms
- Duration of Therapy, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Cross Infection, Drug Administration Schedule, Female, Humans, Intensive Care Units, Male, Middle Aged, Time Factors, Bacteremia, Treatment Outcome, Community-Acquired Infections, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.